C12N 2795/10341
Use of virus, viral particle or viral elements as a vector
C12N2795/10341 (Use of virus, viral particle or viral elements as a vector) appears on 70 US grants and 85 published applications in this corpus.
Search patents in C12N- Granted patents
- 70
- Published applications
- 85
- Assignees
- 50
- Inventors
- 116
- Latest grant
- 4 Nov 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 5 | 0 |
| 1998 | 3 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 2 | 0 |
| 2002 | 2 | 4 |
| 2003 | 1 | 2 |
| 2004 | 3 | 1 |
| 2005 | 1 | 1 |
| 2006 | 1 | 0 |
| 2007 | 0 | 3 |
| 2008 | 0 | 2 |
| 2009 | 0 | 1 |
| 2010 | 2 | 1 |
| 2011 | 1 | 0 |
| 2012 | 0 | 0 |
| 2013 | 1 | 1 |
| 2014 | 1 | 3 |
| 2015 | 0 | 3 |
| 2016 | 2 | 4 |
| 2017 | 3 | 2 |
| 2018 | 0 | 2 |
| 2019 | 2 | 3 |
| 2020 | 2 | 7 |
| 2021 | 3 | 10 |
| 2022 | 9 | 14 |
| 2023 | 10 | 9 |
| 2024 | 7 | 8 |
| 2025 | 7 | 2 |
| 2026 | 0 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2795/10343Viral genome or elements thereof as genetic vectorIndexing code64
- C12N 2795/10344Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code6
- C12N 2795/10342Virus or viral particle as vehicleIndexing code4
- C12N 2795/10345Special targeting system for viral vectorsIndexing code2
Recent patents
- Phage-derived particles for in situ delivery of DNA payload into C. acnes population4 Nov 2025US 12,460,216 B2Eligo Bioscience
- Cutibacterium acnes recombinant phages encoding a human protein28 Oct 2025US 12,454,696 B2Eligo Bioscience
- Sequence specific antimicrobials13 May 2025US 12,295,993 B2The Rockefeller University
- Sequence specific antimicrobials29 Apr 2025US 12,285,466 B2The Rockefeller University
- Sequence specific antimicrobials29 Apr 2025US 12,285,467 B2The Rockfeller University
- Cutibacterium acnes recombinant phages, method of production and uses thereof6 Aug 2026US 2026/0226484 A1Eligo Bioscience
- Phage-derived particles for in situ delivery of dna payload into c. acnes population23 Apr 2026US 2026/0109991 A1Eligo Bioscience
- Sequence specific antimicrobials7 Aug 2025US 2025/0249078 A1The Rockefeller University
- Bacteriophage lambda-vaccine system13 Mar 2025US 2025/0082745 A1The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Phage-derived particles for in situ delivery of dna payload into c. acnes population1 Aug 2024US 2024/0254496 A1Eligo Bioscience
Most cited
By later US patents
- Viruses with recombinant surface proteins96US 4,593,002 AThe Salk Institute Biotechnology/Industrial Associates, Inc. · 1986
- Human erythropoietin gene; high level expression in stably transfected mammalian cells65US 5,688,679 AUniversity of Washington · 1997
- D29 shuttle phasmids and uses thereof50US 5,773,267 AAlbert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University · 1998
- Sequence specific antimicrobials39US 10,660,943 B2The Rockefeller University · 2020
- Quantitative detection of specific nucleic acid sequences using lambdoid bacteriophages linked by oligonucleotides to solid support39US 5,679,510 AHybridon, Inc. · 1997